Stock Library / SNY

SNY Unclassified Latest YouTube: Q2 2026 Published 2026-08-02

SNY

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest on YouTube Latest on Podbean Apple Podcasts Amazon Music iHeartRadio YouTube Music Company Website Back to Library

Latest earnings video

Sanofi (SNY): Sales +18%, Guidance RAISED — the Stock FELL. Is SNY Stock a Buy?

Published 2026-08-02

Open YouTube Spotify Show Open Podbean Apple Podcasts

Library coverage

Episodes tracked

1

Episodes linked

1

Latest video

Q2 2026

2026-08-02

Podcast available

Yes

Current price

$42.95

-0.17 (-0.39%)

Trailing / Forward P/E

22.97x

Forward: 8.06x

Market cap / Volume

—

Volume: —

Revenue / Earnings Growth

14.6%

Earnings: -91.2%

Margins

21.0% op

Gross: 73.5% · Net: 8.1%

Balance sheet

0.99x current

Debt / Equity: 33.9

52-week range / Beta

$40.89 - $52.68

Beta: 0.28

Analyst target

$54.61

Upside: 27.1%

Cash / shareholder return

6.12% FCF yield

Dividend yield: 9.56%

Company context

Industry: Drug Manufacturers - General

Country: France

Employees: —

Price to book: 1.29x

Return on equity: 5.7%

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Price chart

Market context for SNY

Competitive view

SNY vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

SNY latest YouTube video thumbnail

SNY

SNY

YouTube Podbean

Latest video

Q2 2026

Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.

Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.

Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.

Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.

SS&C Technologies Holdings Inc. latest YouTube video thumbnail

SS&C Technologies Holdings Inc.

SSNC

YouTube Podbean

Latest video

Q2 2026

Growth profile looks strong right now, with above-average top-line and/or earnings momentum.

Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.

Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.

Balance-sheet leverage is elevated, so investors should watch refinancing costs and how much flexibility management really has.

Danaher Corporation latest YouTube video thumbnail

Danaher Corporation

DHR

YouTube Podbean

Latest video

Q2 2026

Growth profile looks strong right now, with above-average top-line and/or earnings momentum.

Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.

Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.

Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.

Market Cap

More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.

SNY

$102.91B

SNY

SSNC

$18.63B

SS&C Technologies Holdings Inc.

DHR

$138.84B

Danaher Corporation

Trailing P/E

Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.

SNY

23.0x

SNY

SSNC

22.8x

SS&C Technologies Holdings Inc.

DHR

35.1x

Danaher Corporation

Forward P/E

Forward P/E is often a better read on what investors are paying for the next year of earnings power.

SNY

8.1x

SNY

SSNC

10.3x

SS&C Technologies Holdings Inc.

DHR

21.2x

Danaher Corporation

Revenue Growth

Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.

SNY

14.6%

SNY

SSNC

10.3%

SS&C Technologies Holdings Inc.

DHR

5.5%

Danaher Corporation

Earnings Growth

Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.

SNY

-91.2%

SNY

SSNC

34.7%

SS&C Technologies Holdings Inc.

DHR

59.7%

Danaher Corporation

Operating Margin

Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.

SNY

21.0%

SNY

SSNC

24.6%

SS&C Technologies Holdings Inc.

DHR

19.8%

Danaher Corporation

Gross Margin

Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.

SNY

73.5%

SNY

SSNC

48.1%

SS&C Technologies Holdings Inc.

DHR

58.8%

Danaher Corporation

Net Margin

Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.

SNY

8.1%

SNY

SSNC

13.2%

SS&C Technologies Holdings Inc.

DHR

15.9%

Danaher Corporation

Return on Equity

ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.

SNY

5.7%

SNY

SSNC

12.6%

SS&C Technologies Holdings Inc.

DHR

7.6%

Danaher Corporation

Free Cash Flow Yield

Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.

SNY

6.1%

SNY

SSNC

7.0%

SS&C Technologies Holdings Inc.

DHR

3.1%

Danaher Corporation

Debt to Equity

Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.

SNY

33.89x

SNY

SSNC

115.90x

SS&C Technologies Holdings Inc.

DHR

52.97x

Danaher Corporation

Current Ratio

A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.

SNY

0.99x

SNY

SSNC

1.06x

SS&C Technologies Holdings Inc.

DHR

1.65x

Danaher Corporation

Beta

Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.

SNY

0.28

SNY

SSNC

1.09

SS&C Technologies Holdings Inc.

DHR

0.80

Danaher Corporation

Dividend Yield

Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.

SNY

9.6%

SNY

SSNC

0.7%

SS&C Technologies Holdings Inc.

DHR

0.7%

Danaher Corporation

Analyst Upside

Higher analyst upside suggests the Street still sees room between current price and consensus fair value.

SNY

27.1%

SNY

SSNC

16.3%

SS&C Technologies Holdings Inc.

DHR

15.4%

Danaher Corporation

Related research

Non-quarter videos featuring SNY

Special-topic videos, explainers, and shorts connected to this ticker.

All Research Sections

Shorts and Clips 2026-08-01

Sanofi (SNY): 8.7x Earnings — and the Stock FELL on a Guidance RAISE

A fast Charged Alpha clip pointing viewers into the latest earnings coverage.

YouTube

Episode timeline

Episode archive for SNY

Each row is one earnings episode with every verified platform link available.

Q2 2026

Episode live

2026-08-02

Published youtube podcast complete

Sanofi (SNY): Sales +18%, Guidance RAISED — the Stock FELL. Is SNY Stock a Buy?

Quarterly earnings-analysis entry for SNY. Use the links on the right to open the video or podcast episode.

YouTube Spotify Show Podcast Apple Podcasts Amazon Show iHeart Show YouTube Music